Samsung Biologics has signed a 737.3 billion won ($566 million) contract manufacturing agreement with an unnamed U.S. pharmaceutical company, extending its streak of major deals in 2025. The six-year, eight-month contract represents 16.2% of the South Korean company’s consolidated sales from last year.
The deal follows a record 2.07 trillion won agreement with a European pharmaceutical company in January, bringing Samsung Bio’s total orders this year to 2.81 trillion won – already 52% of its record-setting 2024 order value.
The contract comes just days after Samsung Biologics reported first-quarter consolidated revenue of 1.3 trillion won, driven by the stable performance of its recently completed production facilities. The company’s Plant 5, which began operations this month, added 180,000 liters of biomanufacturing capacity to meet growing global demand for contract manufacturing services.
Industry analysts note this latest agreement further solidifies Samsung Bio’s position among the world’s leading contract development and manufacturing organizations (CDMOs). With a market capitalization of approximately $51 billion as of late March, the company continues to gain market share in the highly competitive pharmaceutical manufacturing sector.
Per the announcement, the identity of the U.S. pharmaceutical company will remain confidential until December 2031 – an unusually long confidentiality period that reflects the strategic nature of the partnership.
